APA (7th ed.) Citation

Powderly, J., Bendell, J., Carneiro, B., Italiano, A., Mercadé, T. M., Alvarez, E. C., . . . Gascó -Hernandez, A. (2020). 1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. Annals of Oncology, 31, S728. https://doi.org/10.1016/j.annonc.2020.08.1193

Chicago Style (17th ed.) Citation

Powderly, J., et al. "1073TiP A Phase I, First-in-human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumours." Annals of Oncology 31 (2020): S728. https://doi.org/10.1016/j.annonc.2020.08.1193.

MLA (9th ed.) Citation

Powderly, J., et al. "1073TiP A Phase I, First-in-human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumours." Annals of Oncology, vol. 31, 2020, p. S728, https://doi.org/10.1016/j.annonc.2020.08.1193.